Le Lézard
Classified in: Health, Covid-19 virus
Subjects: LAW, AVO, DEI

PROJECT ON FAIR REPRESENTATION WARNS NEW YORK DEPARTMENT OF HEALTH ABOUT RACIALLY DISCRIMINATORY PRIORITIZATION OF COVID-19 TREATMENTS


AUSTIN, Texas, Jan. 19, 2022 /PRNewswire/ -- Late yesterday, the Project on Fair Representation sent a letter to New York Department of Health Acting Commissioner Mary T. Basset warning the Department about serious legal problems in the Department's new racially discriminatory guidance on the prioritization of COVID-19 treatments.

The letter notes that the Department's policy already has resulted in a lawsuit and warns the State will surely be sued again if it continues to prioritize treatments for certain racial and ethnic groups over others.

Specifically, the letter notes that, according to the Department's December 29th guidance, "Non-white race or Hispanic/Latino ethnicity should be considered a risk factor, as longstanding systemic health and social inequities have contributed to an increased risk of severe illness and death from COVID-19."

Edward Blum, president of the Project on Fair Representation said, "if permitted to continue, this policy will lead to needless loss of life and will illegally perpetuate immoral racial categories."

Michael Buschbacher, an attorney at Boyden Gray & Associates said, "New York's racially discriminatory treatment plan reads like something from the pages of a 1920s racialist newsletter claiming that 'whites' are somehow inherently more resistant to disease than members of other races. This pseudo-scientific claptrap is wrong and immoral. The shortage of COVID-19 therapeutics is bad enough?New Yorkers of all races deserve better than having these lifesaving treatments rationed based on the color of their skin."

Contact: Edward Blum
703-505-1922
[email protected]

SOURCE The Project on Fair Representation


These press releases may also interest you

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...



News published on and distributed by: